Protagonist Therapeutics (NASDAQ:PTGX) Director William Waddill Sells 20,000 Shares

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Director William Waddill sold 20,000 shares of the company’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $83.68, for a total value of $1,673,600.00. Following the completion of the transaction, the director owned 7,825 shares in the company, valued at $654,796. This represents a 71.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Protagonist Therapeutics Stock Performance

PTGX stock opened at $84.49 on Friday. The firm has a 50 day simple moving average of $85.65 and a 200 day simple moving average of $73.67. Protagonist Therapeutics, Inc. has a 52 week low of $33.70 and a 52 week high of $96.54. The stock has a market cap of $5.28 billion, a P/E ratio of 136.28 and a beta of 2.26.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Thursday, November 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). The company had revenue of $4.71 million during the quarter, compared to analysts’ expectations of $5.41 million. Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%. Sell-side analysts predict that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Hedge Funds Weigh In On Protagonist Therapeutics

Institutional investors have recently made changes to their positions in the business. Farther Finance Advisors LLC grew its holdings in Protagonist Therapeutics by 110.6% in the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after buying an additional 156 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in shares of Protagonist Therapeutics in the second quarter valued at approximately $27,000. Bessemer Group Inc. boosted its position in shares of Protagonist Therapeutics by 171.0% in the second quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock valued at $28,000 after acquiring an additional 318 shares during the period. Salomon & Ludwin LLC acquired a new stake in shares of Protagonist Therapeutics in the third quarter worth $29,000. Finally, CWM LLC increased its position in Protagonist Therapeutics by 201.5% during the second quarter. CWM LLC now owns 609 shares of the company’s stock worth $34,000 after acquiring an additional 407 shares during the period. 98.63% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Wedbush boosted their price target on Protagonist Therapeutics from $70.00 to $86.00 and gave the company an “outperform” rating in a research note on Tuesday, October 28th. BTIG Research reiterated a “buy” rating and issued a $82.00 target price on shares of Protagonist Therapeutics in a research note on Tuesday, October 28th. Citizens Jmp upped their price objective on shares of Protagonist Therapeutics from $69.00 to $102.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. BMO Capital Markets reissued an “outperform” rating on shares of Protagonist Therapeutics in a research report on Monday, October 13th. Finally, Truist Financial boosted their price target on Protagonist Therapeutics from $88.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $91.64.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.